3-溴-5-氟苯甲酰氯 | 887266-90-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-5-氟苯甲酰氯
• 英文名称: 3-bromo-5-fluorobenzoyl chloride
• CAS: 887266-90-2
• 化学式: C₇H₃BrClFO
• 分子量: 237.456
• InChiKey: RGMMCYNLNAUIJX-UHFFFAOYSA-N

物化性质

• 沸点：
  250℃
• 密度：
  1.742
• 闪点：
  105℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P271,P280,P260,P271,P280
• 危险品运输编号：
  3265
• 危险性描述：
  H314,H302+H312+H332

反应信息

• 作为反应物：
  描述：

  3-溴-5-氟苯甲酰氯 在 ammonium hydroxide 、 氯化亚砜 作用下， 反应 18.0h， 生成 3-溴-5-氟苯腈
  参考文献：
  名称：

  Potent mGluR5 antagonists: Pyridyl and thiazolyl-ethynyl-3,5-disubstituted-phenyl series

  摘要：

  We report the synthesis of four series of 3,5-disubstituted-phenyl ligands targeting the metabotropic glutamate receptor subtype 5: (2-methylthiazol-4-yl)ethynyl (1a-j,), (6-methylpyridin-2-yl)ethynyl (2a-j), (5-methylpyridin-2-yl)ethynyl (3a-j,), and (pyridin-2-yl)ethynyl (4a-j,). The compounds were evaluated for antagonism of glutamate-mediated mobilization of internal calcium in an mGluR5 in vitro assay. All compounds were found to be full antagonists and exhibited low nanomolar to subnanomolar activity. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.047
• 作为产物：
  描述：

  3-溴-5-氟苯腈 在 氯化亚砜 、 水 、 sodium hydroxide 作用下， 反应 4.0h， 生成 3-溴-5-氟苯甲酰氯
  参考文献：
  名称：

  Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development

  摘要：

  AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.100

文献信息

• [EN] ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM<br/>[FR] INHIBITEURS ISOINDOLINONE DE L'INTERACTION MDM2-P53 ET PROCÉDÉS DE PRÉPARATION DE CES DERNIERS
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2018178691A1

  公开（公告）日：2018-10-04

  The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1- (oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4- chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H- isoindol-2-yl]-2-methylpropanoic acid and its salts.

  该发明涉及制备异吲哚啉-1-酮衍生物的方法，特别是制备(2S,3S)-3-(4-氯苯基)-3-[(1R)-1-(4-氯苯基)-7-氟-5-[(1S)-1-羟基-1-(氧戊-4-基)丙基]-1-甲氧基-3-酮基-2,3-二氢-1H-异吲哚-2-基]-2-甲基丙酸的方法。该发明还涉及化合物(2S,3S)-3-(4-氯苯基)-3-[(1R)-1-(4-氯苯基)-7-氟-5-[(1S)-1-羟基-1-(氧戊-4-基)丙基]-1-甲氧基-3-酮基-2,3-二氢-1H-异吲哚-2-基]-2-甲基丙酸及其盐的晶型形式。
• Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：——

  公开号：US20030055085A1

  公开（公告）日：2003-03-20

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  本发明提供了作为代谢型谷氨酸受体拮抗剂的化合物和药物组合物，用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。
• AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES
  申请人：Genentech, Inc

  公开号：US20130324516A1

  公开（公告）日：2013-12-05

  The invention provides novel compounds having the general formula: wherein A, R 1 , R 2 and R 3 are as defined herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有以下一般式的新化合物： 其中A，R1，R2和R3如本文所定义，包括这些化合物的组合物和使用这些化合物的方法。
• [EN] BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS D'ACIDE BIARYL-PROPIONIQUE ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2014154727A1

  公开（公告）日：2014-10-02

  The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

  本发明涉及式(I)的化合物，其中X、R、R1、R2、D、E1、E2、E3、E4、G1、G2、G3和G4在权利要求中所示的含义，这些化合物是有价值的药用活性化合物。它们是蛋白酶卡特普辛A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及制备式(I)化合物的方法，它们的用途以及包含它们的药物组合物。
• Biaryl-propionic acid derivatives and their use as pharmaceuticals
  申请人：SANOFI

  公开号：US20140296239A1

  公开（公告）日：2014-10-02

  The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及具有以下式I的化合物，其中X、R、R1、R2、D、E1、E2、E3、E4、G1、G2、G3和G4在权利要求中所示的含义，这些化合物是有价值的药用活性化合物。它们是蛋白酶卡特普辛A的抑制剂，可用于治疗动脉粥样硬化、心力衰竭、肾脏疾病、肝脏疾病或炎症性疾病等疾病。此外，本发明还涉及制备具有式I的化合物的方法，它们的用途以及包含它们的药物组合物。